Advanced Melanoma Resistance Mechanisms to Current Therapies

被引：8

作者：

Haugh, Alexandra M. ^{[1
]}

Salama, April K. S. ^{[2
]}

Johnson, Douglas B. ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, 719 Thompson Lane,Suite 20400, Nashville, TN 37204 USA

[2] Duke Univ, Med Ctr, Dept Med, 20 Duke Med Cir, Durham, NC 27710 USA

[3] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Med, 777 PRB,2220 Pierce Ave, Nashville, TN 37232 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 01期

关键词：

Immune checkpoint inhibitor; Immunotherapy; Resistance; BRAF inhibitor; MEK inhibitor; Melanoma; BRAF INHIBITOR RESISTANCE; IMMUNE CHECKPOINT BLOCKADE; ADVANCED BRAF(V600)-MUTANT MELANOMA; EXOME ANALYSIS REVEALS; PD-1; BLOCKADE; ACQUIRED-RESISTANCE; TUMOR MICROENVIRONMENT; T-CELLS; BRAF(V600E) INHIBITION; NEOANTIGEN LANDSCAPE;

D O I：

10.1016/j.hoc.2020.09.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Novel therapeutic agents introduced over the past decade, including immune checkpoint inhibitors and targeted therapies, have revolutionized the management of metastatic melanoma and significantly improved patient outcomes. Although robust and durable responses have been noted in some cases, treatment is often limited by innate or acquired resistance to these agents. This article provides an overview of known and suspected mechanisms involved with acquired resistance to BRAF/MEK inhibitors as well as developing insights into innate and acquired resistance to checkpoint inhibitors in patients with melanoma. © 2020 Elsevier Inc.

引用

页码：111 / 128

页数：18

共 140 条

[1] Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3 [J].

Abel, Ethan V. ;

Basile, Kevin J. ;

Kugel, Curtis H., III ;

Witkiewicz, Agnieszka K. ;

Le, Kaitlyn ;

Amaravadi, Ravi K. ;

Karakousis, Giorgos C. ;

Xu, Xiaowei ;

Xu, Wei ;

Schuchter, Lynn M. ;

Lee, Jason B. ;

Ertel, Adam ;

Fortina, Paolo ;

Aplin, Andrew E. .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (05) :2155-2168

[2] Continuous versus intermittent BRAF and MEK inhibition in patients withBRAF-mutated melanoma: a randomized phase 2 trial [J].

Algazi, Alain P. ;

Othus, Megan ;

Daud, Adil, I ;

Lo, Roger S. ;

Mehnert, Janice M. ;

Thach-Giao Truong ;

Conry, Robert ;

Kendra, Kari ;

Doolittle, Gary C. ;

Clark, Joseph, I ;

Messino, Michael J. ;

Moore, Dennis F., Jr. ;

Lao, Christopher ;

Faller, Bryan A. ;

Govindarajan, Rangaswamy ;

Harker-Murray, Amy ;

Dreisbach, Luke ;

Moon, James ;

Grossmann, Kenneth F. ;

Ribas, Antoni .

NATURE MEDICINE, 2020, 26 (10) :1564-+

[3] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Zhang, Theresa ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Zahnow, Cynthia A. ;

Baylin, Stephen B. ;

Scharpf, Robert B. ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2017, 7 (03) :264-276

[4]

[Anonymous], 2017, P AM SOC CLIN ON S15

[5]

Ascierto Paolo A, 2018, Am Soc Clin Oncol Educ Book, V38, P751, DOI 10.1200/EDBK_199047

[6] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J].

Ascierto, Paolo A. ;

McArthur, Grant A. ;

Dreno, Brigitte ;

Atkinson, Victoria ;

Liszkay, Gabrielle ;

Di Giacomo, Anna Maria ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Dutriaux, Caroline ;

Garbe, Claus ;

Yan, Yibing ;

Wongchenko, Matthew ;

Chang, Ilsung ;

Hsu, Jessie J. ;

Koralek, Daniel O. ;

Rooney, Isabelle ;

Ribas, Antoni ;

Larkin, James .

LANCET ONCOLOGY, 2016, 17 (09) :1248-1260

[7] Combination of Alphavirus Replicon Particle-Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates [J].

Avogadri, Francesca ;

Zappasodi, Roberta ;

Yang, Arvin ;

Budhu, Sadna ;

Malandro, Nicole ;

Hirschhorn-Cymerman, Daniel ;

Tiwari, Shakuntala ;

Maughan, Maureen F. ;

Olmsted, Robert ;

Wolchok, Jedd D. ;

Merghoub, Taha .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (05) :448-458

[8] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].

Ayers, Mark ;

Lunceford, Jared ;

Nebozhyn, Michael ;

Murphy, Erin ;

Loboda, Andrey ;

Kaufman, David R. ;

Albright, Andrew ;

Cheng, Jonathan D. ;

Kang, S. Peter ;

Shankaran, Veena ;

Piha-Paul, Sarina A. ;

Yearley, Jennifer ;

Seiwert, Tanguy Y. ;

Ribas, Antoni ;

McClanahan, Terrill K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940

[9] Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation [J].

Bald, Tobias ;

Landsberg, Jennifer ;

Lopez-Ramos, Dorys ;

Renn, Marcel ;

Glodde, Nicole ;

Jansen, Philipp ;

Gaffal, Evelyn ;

Steitz, Julia ;

Tolba, Rene ;

Kalinke, Ulrich ;

Limmer, Andreas ;

Jonsson, Goran ;

Hoelzel, Michael ;

Tueting, Thomas .

CANCER DISCOVERY, 2014, 4 (06) :674-687

[10] Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade [J].

Benci, Joseph L. ;

Xu, Bihui ;

Qiu, Yu ;

Wu, Tony J. ;

Dada, Hannah ;

Twyman-Saint Victor, Christina ;

Cucolo, Lisa ;

Lee, David S. M. ;

Pauken, Kristen E. ;

Huang, Alexander C. ;

Gangadhar, Tara C. ;

Amaravadi, Ravi K. ;

Schuchter, Lynn M. ;

Feldman, Michael D. ;

Ishwaran, Hemant ;

Vonderheide, Robert H. ;

Maity, Amit ;

Wherry, E. John ;

Minn, Andy J. .

CELL, 2016, 167 (06) :1540-+

← 1 2 3 4 5 6 7 8 9 10 →